Alicyclic Ring Patents (Class 514/719)
  • Patent number: 10384997
    Abstract: The present disclosure provides biostable cannabinoid compounds according to Formula I: and methods for synthesizing and enhancing the biological concentrations of the compounds, where R1, R2, and R3 are defined as set forth in the disclosure.
    Type: Grant
    Filed: November 15, 2017
    Date of Patent: August 20, 2019
    Assignee: Teewinot Technologies Limited
    Inventors: Malcolm J. Kavarana, Richard C. Peet, Jeffrey M. Korentur
  • Patent number: 9763894
    Abstract: A method is provided for treating a patient in need of therapy for central nervous system inflammation comprising administering to that patient a therapeutically effective amount of a cannabinoid agonist having efficacy at the CB2 receptor but having substantially no efficacy at the CB1 receptor at that amount.
    Type: Grant
    Filed: December 5, 2007
    Date of Patent: September 19, 2017
    Assignees: Virginia Commonwealth University, Organix, Inc., Temple University
    Inventors: Billy R. Martin, Mohamad Imad Damaj, Martin W. Adler, Ronald F. Tuma, Ming Zhang, Anu Mahadevan, Raj K. Razdan
  • Patent number: 9737495
    Abstract: The present invention relates to a process of extraction and purification of a stilbenoid, pterostilbene, from botanical sources. The process involves obtaining pterostilbene having high degree of purity and the present invention also relates to pure form of pterostilbene obtained. The invention also relates to complexing the pterostilbene with carriers such as cyclodextrin for improving its water solubility and bioavailability. The present invention also describes a process for inhibition of Histone Deacetylases using pterostilbene optionally along with a carrier, and a method of managing Poly Glutamine repeat disorders by the administration of pterostilbene optionally along with a carrier.
    Type: Grant
    Filed: July 30, 2009
    Date of Patent: August 22, 2017
    Assignee: Indus Biotech Private Limited
    Inventors: Sunil Bhaskaran, Mohan Vishwaraman
  • Patent number: 9206103
    Abstract: The subject invention provides a myricanol compound that is in predominant form of (+)-?R,11S-myricanol as compared to (?)-?S,11R-myricanol. In one embodiment, the (+)-?R,11S-myricanol is isolated from Myrica cerifera, and is in about 86% enantiomeric excess of (?)-?S,11R-myricanol. The subject invention also pertains to therapeutic compositions and methods for treatment of neurodegenerative diseases, in particular, neurodegenerative diseases associated with abnormal accumulation of protein tau. Specifically exemplified herein is the therapeutic use of myricanol and myricanone isolated from root barks of Myrica species. Also provided are methods for preparing extracts of the subject invention from Myrica species.
    Type: Grant
    Filed: September 15, 2014
    Date of Patent: December 8, 2015
    Assignee: University of South Florida
    Inventors: Chad Dickey, Matthew Lebar, Bill J. Baker, Jeffrey Jones
  • Patent number: 9005578
    Abstract: One aspect of the present invention relates to compounds, compositions and methods for diagnosis and/or treatment of a subject suffering from an amyloidosis-associated pathological condition. In certain embodiments, the imaging and/or therapeutic agents of the instant invention may be administered to a subject for identification and/or treatment of amyloid deposits. A specific imaging method detects amyloid deposits by administering the imaging agent to the subject and detecting the spatial distribution of the agent. Differential accumulation of the agent is indicative of AD or an amyloidosis-associated pathological condition and can be monitored by using a PET or SPECT camera.
    Type: Grant
    Filed: May 28, 2013
    Date of Patent: April 14, 2015
    Assignees: Fluoropharma, Inc., The General Hospital Corporation
    Inventors: David R. Elmaleh, Timothy M. Shoup, Hongning Fu
  • Publication number: 20150098903
    Abstract: One aspect of the present invention relates to compounds, compositions and methods for diagnosis and/or treatment of a subject suffering from an amyloidosis-associated pathological condition. In certain embodiments, the imaging and/or therapeutic agents of the instant invention may be administered to a subject for identification and/or treatment of amyloid deposits. A specific imaging method detects amyloid deposits by administering the imaging agent to the subject and detecting the spatial distribution of the agent. Differential accumulation of the agent is indicative of AD or an amyloidosis-associated pathological condition and can be monitored by using a PET or SPECT camera.
    Type: Application
    Filed: December 15, 2014
    Publication date: April 9, 2015
    Inventors: David R. Elmaleh, Timothy M. Shoup, Hongning Fu
  • Publication number: 20150086494
    Abstract: A topical formulation comprising a Cannabis derived botanical drug product, wherein the concentration of tetrahydrocannabinol, cannabidiol, or both in the topical formulation is greater than 2 milligrams per kilogram.
    Type: Application
    Filed: September 26, 2014
    Publication date: March 26, 2015
    Inventors: Ronald D. SEKURA, Roscoe M. Moore, JR.
  • Publication number: 20150072029
    Abstract: The subject invention provides a myricanol compound that is in predominant form of (+)-?R,11S-myricanol as compared to (?)-?S,11R-myricanol. In one embodiment, the (+)-?R,11S-myricanol is isolated from Myrica cerifera, and is in about 86% enantiomeric excess of (?)-?S,11R-myricanol. The subject invention also pertains to therapeutic compositions and methods for treatment of neurodegenerative diseases, in particular, neurodegenerative diseases associated with abnormal accumulation of protein tau. Specifically exemplified herein is the therapeutic use of myricanol and myricanone isolated from root barks of Myrica species. Also provided are methods for preparing extracts of the subject invention from Myrica species.
    Type: Application
    Filed: September 15, 2014
    Publication date: March 12, 2015
    Inventors: Chad DICKEY, Matthew LEBAR, Bill J. BAKER, Jeffrey JONES
  • Publication number: 20140314757
    Abstract: The present invention relates to phytocannabinoids for use in the treatment of a breast cancer. In a first embodiment the invention relates to an oral presentation of tetrahydrocannabinol (THC) for use in the treatment of aggressive breast cancer, characterised by overexpression of the Her2 gene. In a second embodiment the invention relates to the phytocannabinoid cannabidiol (CBD) for use in the treatment of aggressive breast cancer, characterised by overexpression of the Her2 gene. In a third embodiment the invention relates to the combination of the phytocannabinoids tetrahydrocannabinol (THC) and cannabidiol (CBD) for use in the treatment of breast cancer or to treat, prevent or to reduce the risk of a cancer metastasising.
    Type: Application
    Filed: October 17, 2012
    Publication date: October 23, 2014
    Inventors: Cristina Sanchez, Manuel Guzman, Stephen Wright, Colin Stott, Maria Munoz Caffarel, Clara Andradas, Eduardo Perz Gomez
  • Publication number: 20140302121
    Abstract: A composition comprising a cannabinoid receptor binding agent contained in a particle for the treatment of skin conditions. The particle may be a nanoparticle, such as nanocrystalline cellulose. The particle may further be modified with functional moieties. Drug delivery properties may be modified by coating the particles or using vesicles to deliver the cannabinoid receptor binding agent and particle. A substrate may be used to deliver the composition to the skin.
    Type: Application
    Filed: June 20, 2014
    Publication date: October 9, 2014
    Applicant: Wet Inc.
    Inventor: Jonathan Bevier
  • Publication number: 20140296242
    Abstract: Some embodiments of this invention include methods for treating disease and methods for administering a compound of the invention. In some aspects of the invention, diseases can be treated by administration of compositions comprising a compound of the invention. Pharmaceutical compositions of some embodiments of the present invention comprise a compound of the invention.
    Type: Application
    Filed: April 27, 2012
    Publication date: October 2, 2014
    Applicant: UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.
    Inventors: J. Chistopher States, Ben Frazier Taylor, John O. Trent
  • Publication number: 20140248263
    Abstract: Compounds having a structure of Formula I: wherein G, a, Q, L2, R1, R2, R3, R4, R5 and R6 are as defined herein are provided. Uses of such compounds for treatment of various indications, including prostate cancer as well as methods of treatment involving such compounds are also provided.
    Type: Application
    Filed: April 6, 2012
    Publication date: September 4, 2014
    Applicants: THE UNIVERSITY OF BRITISH COLUMBIA, BRITISH COLUMBIA CANCER AGENCY BRANCH
    Inventors: Raymond John Andersen, Javier Garcia Fernandez, Marianne Dorothy Sadar, Nasrin Mawji, Carmen Adriana Banuelos, Jun Wang
  • Publication number: 20140243404
    Abstract: This disclosure is related to halonium compounds useful for cyclization of polyenes, alkenoic acids, and alkenyl alkyl ethers, and halogenation of aromatic compounds. The synthesis of such halonium compounds, compounds made using such halonium compounds, and synthesis of natural compounds, including decalins, using the halonium compounds is also disclosed.
    Type: Application
    Filed: September 13, 2011
    Publication date: August 28, 2014
    Applicant: The Trustees of Columbia University in the City of New York
    Inventors: Scott Alan Snyder, Daniel S. Treitler, Alexandria P. Brucks, Andreas Gollner, Maria I. Chiriac, Nathan E. Wright, Jason J. Pflueger, Steven P. Breazzano
  • Patent number: 8796326
    Abstract: A fire ant killer chemical composition (the “FAK Composition”) for effective killing of fire ants where the FAK Composition utilizes a minimal amount of active ingredients thereby significantly reducing safety concerns with respect to the use of said active ingredients, the FAK composition having a dish detergent composition and an insecticide composition.
    Type: Grant
    Filed: January 4, 2012
    Date of Patent: August 5, 2014
    Inventor: Harold V. Hutchins
  • Patent number: 8765994
    Abstract: The present invention includes the use of pelorol, related compounds and pharmaceutical compositions thereof as modulators of SHIP 1 activity. This invention also provides novel terpene compounds capable of modulating SHIP 1 activity and methods of synthesis thereof.
    Type: Grant
    Filed: August 19, 2011
    Date of Patent: July 1, 2014
    Assignee: The University of British Columbia
    Inventors: Raymond Andersen, David E. Williams, Alice Mui, Christopher Ong, Gerald Krystal, Lu Yang
  • Publication number: 20140105839
    Abstract: The present invention relates to a compound of the following formula (I): as well as its process of preparation, pharmaceutical and cosmetics composition comprising it and use thereof, notably as an inhibitor of the sodium-dependent glucose co-transporter, such as SGLT1, SGLT2 and SGLT3, in particular in the treatment or prevention of diabetes, and more particularly type-II diabetes, diabetes-related complications, such as arthritis of the lower extremities, cardiac infarction, renal insufficiency, neuropathy or blindness, hyperglycemia, hyperinsulinemia, obesity, hypertriglyceridemia, X syndrome and arteriosclerosis, as well as for its use as an anticancer, anti-infective, anti-viral, anti-thrombotic or anti-inflammatory drug, or for lightening, bleaching, depigmenting the skin, removing blemishes from the skin, particularly age spots and freckles, or preventing pigmentation of the skin.
    Type: Application
    Filed: May 29, 2012
    Publication date: April 17, 2014
    Applicant: TF-CHEM
    Inventors: Geraldine Deliencourt-Godefroy, Lenaig Lopes
  • Patent number: 8641816
    Abstract: Provided are new functionalized surfactants and methods of their preparation and use. The surfactants are compounds of formula I: wherein R1, R2, and R3 are as defined herein.
    Type: Grant
    Filed: October 21, 2010
    Date of Patent: February 4, 2014
    Assignee: Dow Global Technologies LLC
    Inventors: Matthias S. Ober, Edward D. Daugs, Wanglin Yu, Cynthia L. Rand
  • Publication number: 20130315827
    Abstract: One aspect of the present invention relates to compounds, compositions and methods for diagnosis and/or treatment of a subject suffering from an amyloidosis-associated pathological condition. In certain embodiments, the imaging and/or therapeutic agents of the instant invention may be administered to a subject for identification and/or treatment of amyloid deposits. A specific imaging method detects amyloid deposits by administering the imaging agent to the subject and detecting the spatial distribution of the agent. Differential accumulation of the agent is indicative of AD or an amyloidosis-associated pathological condition and can be monitored by using a PET or SPECT camera.
    Type: Application
    Filed: May 28, 2013
    Publication date: November 28, 2013
    Applicants: Fluoropharma, Inc., The General Hospital Corporation
    Inventors: David R. Elmaleh, Timothy M. Shoup, Hongning Fu
  • Publication number: 20130217674
    Abstract: Compounds of structure (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2 and A are as defined herein are disclosed. Such compounds have enhanced water solubility and have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Enantioselective methods for preparation of compounds of structure (I), compositions comprising a compound of structure (I) in combination with a pharmaceutically acceptable carrier or diluents and methods of SHIP1 modulation by administration of such compounds to an animal in need thereof are also disclosed.
    Type: Application
    Filed: August 22, 2011
    Publication date: August 22, 2013
    Applicant: THE UNIVERSITY OF BRITISH COLUMBIA
    Inventors: Xiaoxia Wang, Labros George Meimetis, Matthew Bruce Nodwell, Raymond Andersen
  • Publication number: 20130209483
    Abstract: The disclosure relates to cannabinoid derivative compounds, pharmaceutical compositions made thereof, and methods for treating various diseases and disorders including cancer.
    Type: Application
    Filed: November 30, 2012
    Publication date: August 15, 2013
    Applicant: SUTTER WEST BAY HOSPITALS
    Inventor: SUTTER WEST BAY HOSPITALS
  • Publication number: 20130184353
    Abstract: The subject invention provides a myricanol compound that is in predominant form of (+)-?R,11S-myricanol as compared to (?)-?S,11R-myricanol. In one embodiment, the (+)-?R,11S-myricanol is isolated from Myrica cerifera, and is in about 86% enantiomeric excess of (?)-?S,11R-myricanol. The subject invention also pertains to therapeutic compositions and methods for treatment of neurodegenerative diseases, in particular, neurodegenerative diseases associated with abnormal accumulation of protein tau. Specifically exemplified herein is the therapeutic use of myricanol and myricanone isolated from root barks of Myrica species. Also provided are methods for preparing extracts of the subject invention from Myrica species.
    Type: Application
    Filed: July 25, 2011
    Publication date: July 18, 2013
    Applicant: UNIVERSITY OF SOUTH FLORIDA
    Inventors: Chad Dickey, Matthew Lebar, Bill J. Baker, Jeffrey Jones
  • Publication number: 20130143959
    Abstract: The invention relates to an extract and/or one or more natural compounds from plants or parts of plants, respectively, from a genus selected from Schisandra, Illicium, Kadsura, Steganotaenia or Magnolia, for the regulation of body weight, fat loss, and/or management of obesity, in humans or in animals, methods and uses of the same and to the use of the same or mixtures in the manufacture of a pharmaceutical or nutraceutical formulation. The above can further be used to reduce one or more adverse metabolic parameters in a subject. The invention relates also to said extract and/or compound(s) in the treatment or in the preparation of a medicament for treatment of obesity, as well as their preparation. It also relates to pharmaceutical or nutraceutical formulations comprising said extract and/or natural compound(s), which are useful in the regulation of body weight and/or fat loss and/or for the management of obesity.
    Type: Application
    Filed: November 19, 2012
    Publication date: June 6, 2013
    Applicant: INTERMED DISCOVERY GMBH
    Inventor: INTERMED DISCOVERY GMBH
  • Publication number: 20120322889
    Abstract: The invention relates to the use of a compound according to formula (A) or formula (B), where R1, R4 and R5 are H, a glycoside, or an ester independently of each other, as a plant protection agent, wherein the plant protection agent comprises the compound, which is dissolved in a solvent at a concentration of 0.1 ?M to 2 mM.
    Type: Application
    Filed: February 24, 2011
    Publication date: December 20, 2012
    Applicant: TECHNISCHE UNIVERSITAET WIEN
    Inventors: Karl Stich, Thilo Fischer, Christian Gosch
  • Publication number: 20120251492
    Abstract: Provided are a triterpene derivative represented by a general formula (I), a pharmaceutically acceptable salt thereof, and an agent for preventing or treating chronic hepatitis C comprising the triterpene derivative or the salt as an active ingredient: [in the formula (I), R1 represents a carboxyl group, a hydroxymethyl group, —CH2OSO3H, or and R2 represents —OR3 or —O— (CH2) m-OR4, where R3 represents a benzyl group which may be substituted with a hydroxymethyl group, a dimethylaminomethyl group, a phenylaminomethyl group, a morpholinomethyl group, a carboxyl group, or a formyl group, a C1-6 alkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, or a hydroxy C1-6 alkyl group, R4 represents a phenyl group which may be substituted with a carboxyl group, and m represents an integer of 1 to 3, with the proviso that a case where R1 is —CH2OH, and R3 is a C1-6 alkyl group, a C2-6 alkenyl group, or a benzyl group is excluded].
    Type: Application
    Filed: December 15, 2010
    Publication date: October 4, 2012
    Applicant: MEIJI SEIKA PHARMA CO., LTD.
    Inventors: Makoto Ishikawa, Shigeki Suzuki, Makoto Aoki, Nobuto Minowa, Kokichi Suzuki
  • Patent number: 8268292
    Abstract: The present invention relates to obovatol compound isolated from Magnolia obovata Thunb. for the prevention and treatment of anxiety disorders involved with CNS. The obovatol compound isolated from Magnolia obovata Thunb. have potent anti-anxiety activity, verified by an increased percentage of time on the open arms, an increased number of entries into, time spent on, the distal portion of the open arms, and a decreased activity of locomotor. Therefore it can be used as the therapeutics or health care food for treating and preventing anxiety disorders.
    Type: Grant
    Filed: May 4, 2006
    Date of Patent: September 18, 2012
    Assignees: Korea Research Institute of Bioscience and Biotechnology, Chungbuk National University Industry-Academic Cooperation Foundation
    Inventors: Byoung Mog Kwon, Seung Ho Lee, Kwang Hee Son, Jin Tae Hong, Ki Wan Oh, Jeong Ju Seo
  • Patent number: 8193250
    Abstract: The present invention relates generally to methods of inhibiting the onset and progression of Alzheimer's disease (AD), mild cognitive impairment (MCI), and related neurodegenerative disorders involving amyloidosis. The methods involve administering a composition comprising a therapeutically effective amount of D-pinitol to individuals who are at risk of developing the disease or have one or more symptoms of the disease. The invention also relates to methods of treating or preventing Alzheimer's disease or MCI that involve the use of such compositions. The invention further provides methods to promote the general health of the nervous system through administration of active ingredient compositions. The invention further relates to animal and cellular systems for the study of AD, MCI, and related disorders, and the identification of reagents useful in treating amyloidosis. The invention further provides methods to inhibit AD or MCI in an individual based on reducing caloric intake by the individual.
    Type: Grant
    Filed: October 21, 2005
    Date of Patent: June 5, 2012
    Assignee: Mount Sinai School of Medicine
    Inventor: Giulio M. Pasinetti
  • Publication number: 20120129925
    Abstract: The present invention includes the use of pelorol, related compounds and pharmaceutical compositions thereof as modulators of SHIP 1 activity. This invention also provides novel terpene compounds capable of modulating SHIP 1 activity and methods of synthesis thereof.
    Type: Application
    Filed: August 19, 2011
    Publication date: May 24, 2012
    Applicant: THE UNIVERSITY OF BRITISH COLUMBIA
    Inventors: Raymond Andersen, David E. Williams, Alice Mui, Christopher Ong, Gerald Krystal, Lu Yang
  • Patent number: 8158681
    Abstract: The present invention relates to new methoxylated aromatic compounds. It also relates to novel compositions comprising methoxylated aromatic compounds as well as to the use of these compositions as a medicament, in particular as a medicament for the treatment, co-treatment or prevention of inflammatory disorders.
    Type: Grant
    Filed: February 13, 2007
    Date of Patent: April 17, 2012
    Assignee: DSM IP Assets B.V.
    Inventors: Daniel Raederstorff, Joseph Schwager, Goede Schueler
  • Publication number: 20120052142
    Abstract: A biologically active composition to treat colorectal cancer includes an extract of the plant Schisandra chinensis and a suitable pharmaceutical formulation. The extract can be at least one of gomisin A, angeloylgomisin H, deoxyschisandrin and gomisin N, showing activities against human tumor cell line HT-29 in the range of about 716 ?M to about 43 ?M. A suitable pharmaceutical formulation can be any one of a pill, a tablet, a capsule, a liquid solution, a liquid suspension, a powder, an intravenous solution, a gel and a suppository form. The extract is prepared by grinding the dried berries, extracting with hexane, extracting the marc with dichloromethane, extracting the dichloromethane soluble fraction with ethyl acetate, removing fatty materials in the dichloromethane-ethyl acetate soluble fraction with hexane, and fractionating the total hexane insoluble material extract using analytical high performance liquid chromatography equipped with automated repeat injection/collection cycles.
    Type: Application
    Filed: August 11, 2011
    Publication date: March 1, 2012
    Applicant: Dr. Chang Naturals, LLC
    Inventor: John Noel GNABRE
  • Publication number: 20120053180
    Abstract: This invention relates to a series of substituted cyclohexane containing analogues which are agonists of GPR119 intended to treat metabolic diseases mediated by GPR119 including Type I & II diabetes mellitus. Diabetes mellitus is an ever-increasing threat to human health causing various complications (blindness, kidney failure, neuropathy, heart attack, stroke, etc.). Recently it was found that activation of GPR119 which is highly expressed in pancreatic beta cells causes glucose dependent insulin secretion and GLP-1 release. Many pharmaceuticals are currently developing GPR119 agonists and herein we disclose alternative GPR119 agonists. Our invention describes GPR119 agonists having structural Formula (I), pharmaceutically acceptable salt or solvate of Formula (I), isomer or prodrug of Formula (I), and combination therapy of Formula (I) with other anti-diabetic drugs like DPP-IV inhibitors and/or insulin sensitizers.
    Type: Application
    Filed: March 17, 2011
    Publication date: March 1, 2012
    Applicant: CHEMIZON, A DIVISION OF OPTOMAGIC CO., LTD.
    Inventors: Sang Uk Kang, Min Jeong Kim, Byung Nam Kang, Wei Tan, Albert Charles Gyorkos, Suk Young Cho
  • Patent number: 8093302
    Abstract: The present invention relates to novel tetralin ER-? agonist compounds, pharmaceutical compositions thereof, and use of these compounds to treat a ER-? mediated disease such as nocturia, obstructive uropathy, benign prostatic hypertrophy, obesity, dementia, hypertension, incontinence, colon cancer, prostate cancer, infertility, depression, leukemia, inflammatory bowel disease, and arthritis.
    Type: Grant
    Filed: February 10, 2006
    Date of Patent: January 10, 2012
    Assignee: Eli Lilly and Company
    Inventors: Elizabeth Marie Thomas, Bryan Hurst Norman, Julian Stanley Kroin
  • Patent number: 8063102
    Abstract: The present invention relates to novel tetrahydronaphthalen-2-ol derivatives, to pharmaceutical compositions comprising these compounds and to their use in therapy, in particular to their use for the manufacture of a medicament for the prevention or treatment of lower urinary tract symptoms, benign prostate hyperplasia, prostate cancer, hot flushes, anxiety, depression, breast cancer, medullary thyroid carcinoma, ovarian cancer, inflammatory bowel disease, arthritis, endometriosis, and colon cancer.
    Type: Grant
    Filed: March 11, 2010
    Date of Patent: November 22, 2011
    Assignee: N.V. Organon
    Inventors: Herman Thijs Stock, Neeltje Miranda Teerhuis, Gerrit Herman Veeneman
  • Publication number: 20110269842
    Abstract: Provided are compositions including (3R, 4R, 6R)-stereoisomers of phenyl substituted pinenes having CB receptor agonist properties, methods of treating diseases or disorders with the pharmaceutical compositions, and processes for their preparation are also provided.
    Type: Application
    Filed: October 11, 2009
    Publication date: November 3, 2011
    Applicant: Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd.
    Inventors: Itai Bab, Raphael Mechoulam, Aviva Breuer, Naama Mussai
  • Publication number: 20110263539
    Abstract: The present invention provides the use of pelorol analogs of Formula, (I) and pharmaceutical compositions thereof as modulators of SHIP 1 activity. A compound or a pharmaceutical composition of the present invention may be used for the treatment or prophylaxis of an inflammatory, neoplastic, hematopoetic or immune disorder or condition in addition to other disorders and conditions.
    Type: Application
    Filed: June 21, 2007
    Publication date: October 27, 2011
    Applicant: THE UNIVERSITY OF BRITISH COLUMBIA
    Inventors: Raymond Andersen, Matthew Nodwell, Alice Mui
  • Publication number: 20110213026
    Abstract: The invention relates to the use, or methods (especially with regard to animals, especially human, that are in need of such treatment) comprising the use, of an extract and/or one or more natural compounds from plants or parts of plants, respectively, from a genus selected from the group consisting of Schisandra, Illicium, Kadsura, Steganotaenia and Magnolia, alone or as supplement, as active ingredient in the regulation of body weight and/or fat loss and/or for the management of obesity, either in humans or in animals, to the use of said extract and/or natural compound(s) or mixtures in the manufacture of a pharmaceutical or nutraceutical formulation for the regulation of body weight and/or fat loss and/or for the management of obesity either in humans or in animals. The above extract and/or compound(s) can further be used to reduce one or more adverse metabolic parameters in a subject.
    Type: Application
    Filed: July 29, 2008
    Publication date: September 1, 2011
    Applicant: INTERMED DISCOVERY GMBH
    Inventors: Torsten Grothe, Ernst Roemer, Thomas Henkel
  • Publication number: 20110189294
    Abstract: A formulated composition suitable for controlling or preventing pathogenic damage in a plant comprising (A) at least one solid active ingredient having a water solubility of at most 100 ?g/litre at 25° C. at neutral pH, in an amount of at least 1 weight %, based on the total weight of the formulated composition, (B) at least one non-ionic surface active compound having a hydrophile-lipophile balance (HLB) of between 10 and 18, one or more customary formulation auxiliaries, and water; wherein active ingredient (A) is suspended or dispersed in the water, the weight ratio of surface active compound (B) to active ingredient (A) is in the range of from 1.5 to 15.0, provided the minimum amount of surface active compound (B) is at least 6 weight %, based on the total weight of the formulated composition. Also a method of improving pesticide residue levels in agriculture.
    Type: Application
    Filed: May 25, 2009
    Publication date: August 4, 2011
    Applicant: SYNGENTA CROP PROTECTION, INC.
    Inventors: Jason Keiper, Joshua Koon, Sarah Beth Cush, Michael James Hopkinson, Johnny D. Reynolds, Jorge Cisneros, Jennifer Peterson, Roy Boykin
  • Publication number: 20110152373
    Abstract: The present invention provides a new pharmaceutical application of a 15,15-difluoroprostaglandin F2? derivative. As a result of intensive studies in order to find a new pharmaceutical application of a 15,15-difluoroprostaglandin F2? derivative, it was found that, in a European Phase III clinical trial for tafluprost, one of the 15,15-difluoroprostaglandin F2? derivatives, with patients with open-angle glaucoma or ocular hypertension, tafluprost has actions of growing eyelashes, making eyelashes thicker, and changing the color thereof, that is, has an effect of promoting the growth of hair (eyelashes). Therefore, a 15,15-difluoroprostaglandin F2? derivative is useful as a hair growth promoting agent, and is expected to be useful as an active ingredient of a preventive or therapeutic agent for a disease associated with hair such as alopecia and a hair care product or a hair cosmetic product for regrowing hair, growing hair, increasing hair density, nourishing hair, or the like.
    Type: Application
    Filed: September 4, 2009
    Publication date: June 23, 2011
    Applicant: SANTAN PHARMACEUTICAL CO., LTD.
    Inventor: Auli Ropo
  • Publication number: 20110124741
    Abstract: The present invention provides a method of potentiating radiation therapy for treatment of a cancer or tumor comprising administrating to a subject in need thereof a therapeutically effective amount of a radiosensitizer in combination of a radiation therapy to a locus of the cancer or tumor, wherein the radiosensitizer is an extract of Schisandra chinensis (Turcz.) Baill, or the active ingredient isolated therefrom, particularly Schisandrin B.
    Type: Application
    Filed: November 19, 2010
    Publication date: May 26, 2011
    Applicant: ETEN BIOTECHNOLOGY LTD., CO.
    Inventors: I Cheng LAI, Charng-Cherng CHYAU, Chien-Cheng CHEN, I-Hsuan LIN, Chien-Chih CHEN, Heng Ju LAI
  • Publication number: 20110105507
    Abstract: Provided are new functionalized surfactants and methods of their preparation and use. The surfactants are compounds of formula I: wherein R1, R2, and R3 are as defined herein.
    Type: Application
    Filed: October 21, 2010
    Publication date: May 5, 2011
    Inventors: Matthias S. Ober, Edward D. Daugs, Wanglin Yu, Cynthia L. Rand
  • Publication number: 20110065744
    Abstract: A method of inhibiting mucus secretion in an individual that includes administering an effective amount of a composition which comprises guaifenesin.
    Type: Application
    Filed: September 12, 2009
    Publication date: March 17, 2011
    Applicant: Reckitt Benckiser Inc.
    Inventors: Helmut Albrecht, K. Chul Kim, Bruce Rubin, Jeanclare Seagrave, Gail Solomon
  • Patent number: 7884133
    Abstract: Cannabinoid derivatives are known for their function in the central as well as peripheral nervous system. Disclosed are some novel (+)-cannabidiol (CBD) derivatives of the general formula (I) having selective activity in the peripheral, but not in the central nervous system. Use of (+)-CBD derivatives as analgesics, anti-inflammatory and anti-diarrheal agents is also disclosed.
    Type: Grant
    Filed: September 8, 2004
    Date of Patent: February 8, 2011
    Assignees: Yissum Research Development Company of the Hebrew University of Jerusalem, Ariel Ltd.
    Inventors: Raphael Mechoulam, Ester Fride
  • Publication number: 20100261772
    Abstract: The present invention relates to compounds of formula (I) with a variety of therapeutic uses, more particularly the substituted cyclic alkylidene compounds are useful for selective estrogen receptor modulation.
    Type: Application
    Filed: May 24, 2010
    Publication date: October 14, 2010
    Inventors: Jing Fang, Dennis Heyer, Subba Reddy Katamreddy, Kenneth William Batchelor, Richard Dana Caldwell
  • Publication number: 20100240748
    Abstract: The present invention relates to novel tetrahydronaphthalen-2-ol derivatives, to pharmaceutical compositions comprising these compounds and to their use in therapy, in particular to their use for the manufacture of a medicament for the prevention or treatment of lower urinary tract symptoms, benign prostate hyperplasia, prostate cancer, hot flushes, anxiety, depression, breast cancer, medullary thyroid carcinoma, ovarian cancer, inflammatory bowel disease, arthritis, endometriosis, and colon cancer.
    Type: Application
    Filed: March 11, 2010
    Publication date: September 23, 2010
    Inventors: Herman Thijs Stock, Neeltje Miranda Teerhuis, Gerrit Herman Veeneman
  • Publication number: 20100222406
    Abstract: The present invention provides a method for treating a disease or condition in a mammal associated with influx of extracellular calcium via T type calcium channels, which comprises administering to the mammal a therapeutically effective amount of a T type calcium channel inhibitor, a prodrug thereof, or a pharmaceutically acceptable salt of said inhibitor or prodrug, wherein the T type calcium channel inhibitor has a structure represented by Formula (I): Formula (I), wherein R1 is selected from the group consisting of C1-C4 alkyl, hydroxy and C1-C4 alkoxy; X is selected from the group consisting of N and CH; Z is selected from the group consisting of NH, O, S and CH2; R2 is selected from the group consisting of H, halo, NH2, C1-C4 alkyl, hydroxy and C1-C4 alkoxy; and R3 is selected from the group consisting of H, halo, NH2, C1-C4 alkyl, hydroxy and C1-C4 alkoxy.
    Type: Application
    Filed: January 14, 2010
    Publication date: September 2, 2010
    Applicant: UNIVERSITY OF VIRGINIA PATENT FOUNDATION
    Inventors: Lloyd S. Gray, Doris M. Haverstick
  • Publication number: 20100222438
    Abstract: Novel methods and pharmaceutical compositions suitable for modulating bone growth and remodeling, preventing bone diseases, inducing bone growth or repair by cannabinoid receptor-mediated effects on bone cells is disclosed. Methods of identifying bone growth modulating agents are also disclosed.
    Type: Application
    Filed: February 23, 2010
    Publication date: September 2, 2010
    Applicant: Yissum Research Development Company of the Hebrew University of Jerusalem
    Inventors: Itai Bab, Raphael Mechoulam, Andreas Zimmer, Esther Shohami
  • Patent number: 7786098
    Abstract: Combretastatin derivatives of formula (I), preparation and use thereof are disclosed, wherein: Rf is alkyl with 1-8 carbon atoms and 1-17 fluorine atoms, R is amino, substituted amino, hydroxyl, nitro, halo, alkyloxy, phosphate or amino acid side chain. Said derivatives have a capability to inhibit the polymerization of microtubules and are useful in treatment against tumor and neovascularization.
    Type: Grant
    Filed: November 22, 2006
    Date of Patent: August 31, 2010
    Assignee: Zhejiang Dade Pharmaceutical Group Co. Ltd.
    Inventors: Weiping Shen, Jianping Wang, Jianguo Wang, Hongmei Jin, Feng Qian, Fei Wang
  • Publication number: 20100196473
    Abstract: Pharmaceutical compositions with delayed release which contains 6-dimethylaminomethyl-1-(3-methoxyphenyl)-cyclohexane-1,3-diol or a pharmaceutically acceptable salt thereof in a matrix with delayed active ingredient release, wherein the matrix contains 1 to 80 wt. % of one or more hydrophilic or hydrophobic polymers as pharmaceutically acceptable matrix formers and exhibits the following in vitro release rate: 3-35 wt. % (relative to 100 wt. % of active ingredient) of 6-dimethylaminomethyl-1-(3-methoxyphenyl)-cyclohexane-1,3-diol released after 0.5 hours, 5-50 wt. % after 1 hour, 10-75 wt. % after 2 hours, 15-82 wt. % after 3 hours, 30-97 wt. % after 6 hours, more than 50 wt. % after 12 hours, more than 70 wt. % after 18 hours, and more than 80 wt. % after 24 hours.
    Type: Application
    Filed: April 9, 2010
    Publication date: August 5, 2010
    Applicant: Gruenenthal GmbH
    Inventor: Johannes Bartholomaeus
  • Publication number: 20100022631
    Abstract: The compounds D9-tetrahydrocannabinol (THC), cannabidiol (CBD) and capsaicin are useful for prevention, treatment, or both, of hepatic encephalopathy. The compounds capsaicin, 2-arachidonoylglycerol (2-AG), HU-308 and cannabidiol are useful for prevention, treatment, or both, of liver cirrhosis.
    Type: Application
    Filed: April 24, 2009
    Publication date: January 28, 2010
    Applicants: Yissum Research Development Company of the Hebrew University of Jerusalem, Hadasit Medical Research Services & Development Ltd., Aristotle University of Thessaloniki
    Inventors: Elliot BERRY, Yosefa Avraham, Raphael Mechoulam, Yaron Ilan, Yossi Dagon, Iddo Magen, Nicholas Grigoriadis, Theofilos Poutachidis
  • Publication number: 20090239955
    Abstract: Disclosed herein are novel obovatol derivatives represented by Chemical Formula 1, and pharmaceutically acceptable salts thereof. Having the ability to inhibit the growth of cancer cells and induce apoptosis in cancer cells, the derivatives or pharmaceutically acceptable salts thereof are useful in the prevention and treatment of cancer and in the suppression of cancer metastasis. Also, a method for preparing the derivatives, and pharmaceutical compositions comprising the derivatives as active ingredients are disclosed. wherein R1,R2 and R3 are as defined in the specification.
    Type: Application
    Filed: July 28, 2008
    Publication date: September 24, 2009
    Applicant: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY
    Inventors: Byoung-Mog Kwon, Dong Cho Han, Su-Kyung Lee, Hye-Nan Kim, Young-Min Han, Dae-Seop Shin
  • Publication number: 20090215908
    Abstract: The present invention relates to novel synthetic toll like receptor antagonist. The present invention in particular provides compounds, methods and compositions for specifically inhibiting immune stimulation involving TLR ligands, especially TLR-4. The compounds are potentially useful in treatment of inflammation, autoimmunity, allergy, asthma, graft rejection, graft versus host disease, infection, sepsis, cancer and immunodeficiency.
    Type: Application
    Filed: September 23, 2008
    Publication date: August 27, 2009
    Applicant: RELIANCE LIFE SCIENCES PVT. LTD.
    Inventors: Shakti Upadhyay, Yogesh Kanekar, Rajendra Kshirsagar, Vikram Rajagopal, Praneel Datla, Akshaya Bellary, Shiva Prasad Singh